Latest Product Commercialisation News

Latrobe Magnesium Limited has successfully commenced production of Magnesium Oxide at its Hazelwood North Demonstration Plant, marking a significant operational milestone. The company is advancing towards steady-state output and exploring by-product commercialisation.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

Skin Elements Limited reported a 13% revenue increase and a 20% reduction in net loss for FY2025, as it progresses commercial roll-out of its natural biotech products including ECO-Nurture and SuprCuvr.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

TALi Digital has successfully raised $800,000 through a private placement to fuel the commercialisation of its digital health products aimed at enhancing childhood cognitive attention.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

Andromeda Metals has entered exclusive negotiations for a $75 million debt facility to fund the Stage 1A+ development of its Great White Project, alongside operational progress and exploration drilling.

Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.